此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

二甲双胍用于肺癌高危超重或肥胖人群的肺癌化学预防

2026年11月9日 更新者:Northwestern University

二甲双胍用于高危超重或肥胖个体肺癌的化学预防

This phase II trial determines the effect of metformin extended release on the risk for developing lung cancer in overweight/obese patients that are at high-risk for developing lung cancer. Metformin is widely used to treat type II diabetes and has a long history of safety and minimal side effects. At similar dosage, the drug may have potential anti-cancer activity. Metformin use has been associated with improved survival in patients with non-small cell lung carcinoma, a specific type of lung cancer, and it has also been shown to enhance immune mobilization against tumors. This trial aims to see whether metformin extended release as a preventative treatment may lower the chance of developing lung cancer, and whether it may help patients' immune system learn ("reprogram") to lower a certain type of immune cell (called regulatory T cells) that are linked to tumor development.

研究概览

详细说明

PRIMARY OBJECTIVE:

I. To evaluate the effect of metformin treatment on the expression of programmed cell death protein 1 (PD-1) on airway regulatory T cells (Tregs) in overweight and obese individuals at high risk for lung cancer.

SECONDARY OBJECTIVES:

I. Estimated PD-1 expression of pulmonary Tregs change in Cohort B during the wait period (26 weeks with no treatment).

II. To examine the impact of metformin on circulating immune cell subsets of blood.

III. To evaluate the effect of metformin treatment on the expression of PD-1 on airway regulatory T cells (Tregs) in overweight and obese current smokers at high risk for lung cancer

EXPLORATORY OBJECTIVES:

I. To examine the impact of metformin on cancer-related transcriptome features of airway lesions.

II. To examine the impact of metformin on immune profile of pulmonary parenchyma represented by bronchoalveolar lavage (BAL).

III To examine the impact of metformin on histologic progression of abnormal airway lesions.

IV. To examine the impact of metformin on serum adipokines and inflammatory cytokines.

OUTLINE: Participants are randomized to 1 of 2 cohorts.

COHORT A: Former Smokers - Participants receive metformin extended release (ER) orally (PO) once daily (QD) for 26 weeks in the absence of unacceptable toxicity. Participants undergo bronchoscopy biopsy and blood sample collection at screening, and week 13.

COHORT B: Former Smokers - Participants receive no intervention for 26 weeks, then cross-over to cohort A. Participants undergo bronchoscopy biopsy and blood sample collection at screening, at week 26, and at 13 weeks after cross-over to Cohort A.

COHORT C: Current Smokers - Participants receive metformin extended release (ER) orally (PO) once daily (QD) for 26 weeks in the absence of unacceptable toxicity. Participants undergo bronchoscopy biopsy and blood sample collection at screening, and week 13.

After completion of study treatment, participants are followed up at weeks 30-32 (Cohorts A and C) and weeks 56-58 (Cohort B).

研究类型

介入性

注册 (实际的)

50

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • British Columbia
      • Vancouver、British Columbia、加拿大、V6T 2B5
        • University of British Columbia Hospital
      • Vancouver、British Columbia、加拿大、V5Z 1L3
        • BC Cancer Research Centre
    • Colorado
      • Aurora、Colorado、美国、80045
        • Rocky Mountain Regional VA Medical Center
    • New York
      • Buffalo、New York、美国、14263
        • Roswell Park Cancer Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

30年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Former smokers (male and female) with a >= 20 pack year smoking history

  • Quit smoking >= 12 months prior to enrollment

  • Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCOm2012) Lung Cancer Risk Prediction Score > 1.34%

  • Overweight

    • Body mass index (BMI) > 25 and

    • Waist circumference

      • Female > 88 cm (35")
      • Male > 102 cm (40")
  • Age greater than 30 years. Participants younger than 30 years are unlikely to accrue enough smoking exposure followed by enough time after quitting (>12 months) to qualify

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2

  • Leukocytes >= 3,000/microliter

  • Absolute neutrophil count (ANC) >= 1,000/microliter

  • Platelets >= 100,000/microliter

  • Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x IULN

  • Estimated glomerular filtration rate (eGFR) > 45 ml/min/1.73 m^2 (eGFR will be calculated using the equation Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] creatinine)

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured

  • Patients on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible

  • The effects of metformin ER on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately

  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Current or previous diagnosis of diabetes mellitus (type I or type II diabetes)

  • Use of metformin within the past 2 years

  • Use of GLP-1 agonists within 6 weeks prior to enrollment

  • Glycosylated hemoglobin A1C (HbA1c) > 8%

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin ER

  • Participants currently using immunosuppressive medication, including systemic steroids (not inhalational) and episodic use of inhaled steroids are excluded from this trial due to the potential impact of these treatments on the primary trial endpoint

  • Participants receiving any other investigational agents

  • History of chronic alcohol use or abuse defined by any one of the following:

    • Average consumption of 3 or more alcohol containing beverages daily in the past 12 months
    • Consumption of 7 or more alcoholic beverages within a 24 hour period in the past 12 months
  • Acute or chronic liver disease, evidence of hepatitis (infectious or autoimmune), cirrhosis or portal hypertension

  • History of or current condition predisposing to increased risk for lactic acidosis such as: severe congestive heart failure (New York Heart Association [NYHA] class III or IV), metabolic acidosis, severe liver disease, or renal failure

  • Uncontrolled intercurrent illness or psychiatric illness/social situations that would or limit compliance with study requirements

  • Pregnant women are excluded from this study. Metformin ER is a class B agent that was not teratogenic in rats and rabbits at doses representing 3 and 6 times the maximum recommended human daily dose of 2000 mg; however, animal reproduction studies are not always predictive of human response. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with metformin ER, breastfeeding should be discontinued if the mother is treated with metformin ER

  • Biopsy with invasive carcinoma of the lung or carcinoma in situ

    • Participants with prior stage 1 non-small cell lung cancer (NSCLC) diagnosis are allowed to participate, as long as there has been 12 months since the completion of cancer treatment prior to enrollment with no evidence of recurrence or second primary cancer

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort A - Former Smokers (metformin ER)

Participants receive metformin ER PO QD for 26 weeks in the absence of unacceptable toxicity. Participants undergo bronchoscopy biopsy and blood sample collection at screening, and week 13.

Undergo blood sample collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集

Ancillary studies

Undergo biopsy

其他名称:
  • Bx
  • 活组织检查类型

Given PO

其他名称:
  • 噬菌体XR
  • Glumetza
  • ER 盐酸二甲双胍
  • 缓释盐酸二甲双胍
  • 盐酸二甲双胍缓释剂

Undergo bronchoscopy

有源比较器:Cohort B - Former Smokers (metformin ER with waiting period)

Participants receive no intervention for 26 weeks, then cross-over to Cohort A. Participants undergo bronchoscopy biopsy and blood sample collection at screening, at week 26, and at 13 weeks after cross-over to Cohort A.

Undergo blood sample collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集

Ancillary studies

Undergo biopsy

其他名称:
  • Bx
  • 活组织检查类型

Given PO

其他名称:
  • 噬菌体XR
  • Glumetza
  • ER 盐酸二甲双胍
  • 缓释盐酸二甲双胍
  • 盐酸二甲双胍缓释剂

Undergo bronchoscopy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
PD-1 expression of pulmonary regulatory T cells (Tregs) before and after metformin extended release (ER) treatment
大体时间:Pre- to post-treatment

Change from pre- to post-metformin extended release (ER) treatment in cell surface PD-1 expression levels of pulmonary (BAL) Tregs, measured as mean fluorescent intensity (MFI). Changes in MFI due to metformin ER treatment among all n = 40 subjects will be used for the primary analysis.

Pre- to post-treatment

次要结果测量

结果测量
措施说明
大体时间
Estimated PD-1 expression of pulmonary Tregs change in cohort B during the wait period (6 months with no treatment)
大体时间:Randomization to week 26

This is the estimate of change in MFI following the 6-month wait period among n = 20 subjects randomized to the wait-list arm. This will confirm the stability of the PD-1 expression of pulmonary Tregs over time.

Randomization to week 26
Circulating immune cells
大体时间:Pre- to post-treatment

Circulating immune cell composition between blood samples collected pre- and post-metformin ER treatment to assess the effect of metformin ER on circulating immune cells and to identify potential biomarkers of metformin ER response.

Pre- to post-treatment

其他结果措施

结果测量
措施说明
大体时间
Airway gene expression
大体时间:Up to study completion

RNA sequencing of endobronchial biopsies will be performed at visually normal mainstem airway for each participant. The analysis of the RNA seq data will be an unsupervised comparison of differentially expressed genes with and without metformin ER exposure.

Up to study completion
Examination of the immune profile of pulmonary parenchyma represented by bronchoalveolar lavage
大体时间:Pre- to post-treatment

This will compare the immune composition of bronchoalveolar lavage samples of participants before and after metformin exposure. Specifically, the prevalence and composition of myeloid derived suppressor cells (MDSCs) as well as monocyte, macrophage and dendritic cells will be assessed.

Pre- to post-treatment
Histologic progression
大体时间:Up to study completion

Bronchoscopic biopsies of at least 6 standard sites will be graded on the World Health Organization (WHO) scale of dysplasia and assigned numerical scores from 1 (normal) to 8 (invasive cancer). Each lesion will be classified as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) and each response rate will be calculated on a per-site and a per-participant basis. Additional measures of dysplasia will include the average dysplastic score and the dysplasia index (% of sites with dysplasia score >= 3 (mild dysplasia)). Changes in maximum dysplasia will be analyzed using a paired t test to determine whether a reduction occurs.

Up to study completion
Examination of the effect of metformin on systemic adipokines and inflammatory cytokines
大体时间:Pre- to post-treatment

Frozen sera will be analyzed by commercial enzyme-linked immunosorbent assay kits for levels of leptin, adiponectin, resistin, IL6 and TNFalpha. Pre- and post-treatment serum levels will be compared in parametric paired testing.

Pre- to post-treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Saikrishna S Yendamuri、Roswell Park University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年9月9日

初级完成 (实际的)

2026年7月9日

研究完成 (估计的)

2027年6月30日

研究注册日期

首次提交

2021年6月17日

首先提交符合 QC 标准的

2021年6月17日

首次发布 (实际的)

2021年6月18日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • NCI-2021-06112
  • P30CA060553 (美国 NIH 拨款/合同)
  • UG1CA242643 (美国 NIH 拨款/合同)
  • NCI-2021-06112 (注册表标识符:CTRP (Clinical Trial Reporting Program))
  • NCI20-04-01 (其他标识符:Northwestern University)
  • NWU20-04-01 (其他标识符:DCP)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅